These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 19071019)
21. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I). Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738 [TBL] [Abstract][Full Text] [Related]
22. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors. Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226 [TBL] [Abstract][Full Text] [Related]
23. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401 [TBL] [Abstract][Full Text] [Related]
24. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode. Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896 [TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors. Loidreau Y; Marchand P; Dubouilh-Benard C; Nourrisson MR; Duflos M; Lozach O; Loaëc N; Meijer L; Besson T Eur J Med Chem; 2012 Dec; 58():171-83. PubMed ID: 23124214 [TBL] [Abstract][Full Text] [Related]
26. Discovery of XL413, a potent and selective CDC7 inhibitor. Koltun ES; Tsuhako AL; Brown DS; Aay N; Arcalas A; Chan V; Du H; Engst S; Ferguson K; Franzini M; Galan A; Holst CR; Huang P; Kane B; Kim MH; Li J; Markby D; Mohan M; Noson K; Plonowski A; Richards SJ; Robertson S; Shaw K; Stott G; Stout TJ; Young J; Yu P; Zaharia CA; Zhang W; Zhou P; Nuss JM; Xu W; Kearney PC Bioorg Med Chem Lett; 2012 Jun; 22(11):3727-31. PubMed ID: 22560567 [TBL] [Abstract][Full Text] [Related]
27. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities. Lücking U; Siemeister G; Schäfer M; Briem H; Krüger M; Lienau P; Jautelat R ChemMedChem; 2007 Jan; 2(1):63-77. PubMed ID: 17131463 [TBL] [Abstract][Full Text] [Related]
28. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor. Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358 [TBL] [Abstract][Full Text] [Related]
29. Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors. Chen S; Chen L; Le NT; Zhao C; Sidduri A; Lou JP; Michoud C; Portland L; Jackson N; Liu JJ; Konzelmann F; Chi F; Tovar C; Xiang Q; Chen Y; Wen Y; Vassilev LT Bioorg Med Chem Lett; 2007 Apr; 17(8):2134-8. PubMed ID: 17303421 [TBL] [Abstract][Full Text] [Related]
30. Entry into a new class of protein kinase inhibitors by pseudo ring design. Furet P; Caravatti G; Guagnano V; Lang M; Meyer T; Schoepfer J Bioorg Med Chem Lett; 2008 Feb; 18(3):897-900. PubMed ID: 18248988 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors. Caldarelli M; Angiolini M; Disingrini T; Donati D; Guanci M; Nuvoloni S; Posteri H; Quartieri F; Silvagni M; Colombo R Bioorg Med Chem Lett; 2011 Aug; 21(15):4507-11. PubMed ID: 21723120 [TBL] [Abstract][Full Text] [Related]
32. The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase. Malagu K; Duggan H; Menear K; Hummersone M; Gomez S; Bailey C; Edwards P; Drzewiecki J; Leroux F; Quesada MJ; Hermann G; Maine S; Molyneaux CA; Le Gall A; Pullen J; Hickson I; Smith L; Maguire S; Martin N; Smith G; Pass M Bioorg Med Chem Lett; 2009 Oct; 19(20):5950-3. PubMed ID: 19762236 [TBL] [Abstract][Full Text] [Related]
33. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent. Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727 [TBL] [Abstract][Full Text] [Related]
34. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors. Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677 [TBL] [Abstract][Full Text] [Related]
35. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR. Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066 [TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors. Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Miyazawa K; Misawa K; Ohnota H; Isaji M Bioorg Med Chem; 2009 Jan; 17(1):284-94. PubMed ID: 19010686 [TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2. Golub AG; Bdzhola VG; Briukhovetska NV; Balanda AO; Kukharenko OP; Kotey IM; Ostrynska OV; Yarmoluk SM Eur J Med Chem; 2011 Mar; 46(3):870-6. PubMed ID: 21276643 [TBL] [Abstract][Full Text] [Related]
38. Development of pyridopyrimidines as potent Akt1/2 inhibitors. Wu Z; Hartnett JC; Neilson LA; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Hartman GD; Bilodeau MT Bioorg Med Chem Lett; 2008 Feb; 18(4):1274-9. PubMed ID: 18249537 [TBL] [Abstract][Full Text] [Related]
39. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors. Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129 [TBL] [Abstract][Full Text] [Related]
40. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation. Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]